^
    1m
    TACTOPS: TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Completed, Baylor College of Medicine | Trial completion date: May 2027 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    1m
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    MultiTAA T cell therapy
    2ms
    First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. (PubMed, Cancers (Basel))
    Patients enrolled in the phase 1 part of CD-TCR-001 displayed signs of potential clinical and biological activity of MDG1011 among the small number of patients studied. Advanced disease stage and rapid progression in the r/r AML patients limited clinical impact. The acceptable safety profile of MDG1011 merits further investigation of this TCR-T therapy, potentially in patients at an earlier stage of their disease and with lower tumor burden.
    P1 data • Journal • First-in-human
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    HLA-A*02:01
    |
    MDG1011
    3ms
    Study of IMC-P115C in Advanced PRAME-Positive Cancers (clinicaltrials.gov)
    P1, N=140, Recruiting, Immunocore Ltd
    New P1 trial
    3ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Recruiting, Immatics US, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    3ms
    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, Immatics US, Inc. | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2028 --> Jun 2032
    Phase classification • Trial completion date
    |
    Opdivo (nivolumab) • IMA203CD8 • anzutresgene autoleucel (IMA203)
    3ms
    TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=12, Completed, Baylor College of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    MultiTAA T cell therapy
    4ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Immatics US, Inc. | Initiation date: May 2025 --> Aug 2025
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    6ms
    Preferentially Expressed Antigen in Melanoma (PRAME) as a diagnostic and predictive marker in melanocytic tumors: An updated narrative review. (PubMed, Histol Histopathol)
    Nevertheless, PRAME remains a valuable tool in the diagnostic and prognostic evaluation of melanocytic lesions, particularly when histological features are unclear or ambiguous. Further research is needed to refine its role in different melanoma subtypes and to explore its potential as a target for immunotherapy.
    Review • Journal • IO biomarker
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    7ms
    Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) (clinicaltrials.gov)
    P1, N=39, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    7ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Immatics US, Inc.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    8ms
    Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. (PubMed, Nat Med)
    Overall, IMA203 showed promising anti-tumor activity in multiple solid tumors, including refractory melanoma. ClinicalTrials.gov identifier: NCT03686124 .
    P1 data • Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    anzutresgene autoleucel (IMA203)